Acquisition Momentum IBA Dosimetry recently expanded its footprint through the Radcal acquisition, signaling an opportunity to cross-sell QA solutions and integrate imaging capabilities with Radcal’s X-ray expertise to hospitals expanding diagnostic and radiotherapy services.

Integrated QA Platform The myQA iON platform introduced in 2019 and ongoing enhancements position IBA Dosimetry as a single-source provider for both quality assurance and imaging calibration, enabling upsell of comprehensive QA bundles to radiotherapy centers.

Global Reach With headquarters in Germany and subsidiaries in the US and China, there is potential to target regional hospitals and clinics in North America and Asia Pacific for accelerated adoption of dosimetry and QA solutions, leveraging local support teams.

Market Leadership As a leading dosimetry solutions provider with a broad installed base, there is an opportunity to pursue expansion within existing customers through enhanced service contracts, software updates, and interlinked diagnostics for radiotherapy and radiodiagnostics.

Growth Signals Sustained product development and a revenue range that indicates a focused mid-market footprint suggest targeting mid-sized cancer centers and teaching hospitals with scalable QA needs and potential for multi-year procurement deals.